Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 20, 2017
| Title: | Dosage forms of risedronate |
| Abstract: | The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients. |
| Inventor(s): | Dansereau; Richard John (Sherburne, NY), Mosher; Russell Youker (Norwich, NY), Axelrod; Douglas Wayne (Norwich, NY), Sietsema; William Kendall (Norwich, NY) |
| Assignee: | The Procter & Gamble Company (Mason, OH) |
| Application Number: | 09/303,466 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Slovakia | 279589 | ► Subscribe | |||||||||||||||||||||||||||
| Slovakia | 59594 | ► Subscribe | |||||||||||||||||||||||||||
| Russian Federation | 2120798 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 101085 | ► Subscribe | |||||||||||||||||||||||||||
| New Zealand | 245214 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 941894 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 100274734 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2005255687 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | H07501073 | ► Subscribe | |||||||||||||||||||||||||||
| Hungary | 227530 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,681 others who get our Drug Patent Expiration Alerts:
